Martina Weise, MD
While biosimilars for the treatment of patients with cancer have only entered the arena in the last few years, supportive care biosimilars have been used in oncology for about a decade.
Much like recent skepticism over the potential use of trastuzumab (Herceptin) and bevacizumab (Avastin) biosimilars in the EU and the United States, the introduction of biosimilars for filgrastim (Neupogen) and erythropoietin were also met with reluctance, according to Martina Weise, MD.
Now more than ever, though, physicians are beginning to understand the utility and benefits of biosimilars. This will lead to a more competitive market and price decreases for payers and improved access to treatment with biologicals for patients, Weise said.
... to read the full story